Keratan Sulfate, Quantitative by LC-MS/MS, Urine
Also known as: KS U MS
Use
The test is used for the screening and monitoring of patients suspected to have Morquio syndrome (MPS IV), in conjunction with other mucopolysaccharides screen tests. It measures the total keratan sulfate in urine, which is calculated as the sum of the two disaccharides, LacNAc1 and LacNAc2, per milligram of creatinine.
Special Instructions
A morning void is preferred for sample collection. Separate specimens must be submitted if multiple tests are ordered. It is a Laboratory Developed Test (LDT) and has not been cleared or approved by the US Food and Drug Administration.
Limitations
The test is not FDA-approved and is intended for clinical purposes as a Laboratory Developed Test (LDT) performed in a CLIA-certified laboratory. It has technical constraints as a specialty test for Morquio syndrome, which may not encompass all variations of the disease phenotype.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 2161-8
- 11502-2
Result Turnaround Time
3-10 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
2 mL
Minimum Volume
1 mL
Container
ARUP standard transport tube
Collection Instructions
Transfer 2 mL urine to ARUP standard transport tube and freeze immediately. Morning void is preferred.
Patient Preparation
Morning void is preferred.
Storage Instructions
CRITICAL FROZEN. Separate specimens must be submitted with multiple tests are ordered.
Causes for Rejection
Specimens containing preservatives.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | Unacceptable |
| Frozen | 1 month |